Meine Zukunft Innovative Chemie Interviews Inspirierende Job-Links Meine Ausbildung

APEIRON Biologics AG

Firmenlogo

Apeiron Biologics AG is a privately financed Biotech company based in Vienna. Following a licensing deal with GSK in 2010 relating to project APN01 (recombinant human Angiotensin Converting Enzyme 2, rhACE2), Apeiron expanded its project portfolio with a focus on biologic / immunologic therapy of cancer and related conditions. Building on an existing range of innovative in-house projects, Apeiron acquired exclusive rights to hu14.18-IL2 (APN301), a Phase II antibody-based biologic for treatment of Neuroblastoma and other cancers. In addition, Apeiron licensed-in recombinant human Superoxide Dismutase (APN201), a naturally occurring enzyme for treatment of cancer treatment-related side-effects, also in Phase II.

News Focussing on Members

(AVIR Green Hills Biotechnology AG) deltaFLU –innovative vaccines for intranasal spray delivery or oral administration more 

 

(Apeptico) APEPTICO Announces Successful Completion of Phase I Trial with AP301 in Oedematous Respiratory Failure  more 

 

(Intercell) Intercell announces new management structure more 

 

(Eucodis) EUCODIS Bioscience and evocatal enter into alliance more 

 

(Intercell) Staph Bakali new Chief Business Officer more 

 

(Intercell) Intercell acquires antibody technology platform to further exploit its capabilities to combat infectious diseases more 

 

(Apeptico) APEPTICO granted Orphan Drug Designation by FDA for development compound AP301 more